News Across Asia - Page 392

China Briefing

2022 Import-Export Taxes and Duties in China

12/22/2021

We explain China's updated import and export tax rates and duties for 2021, and highlight key issues that foreign companies should take note of.

India Briefing

All You Need to Know About Dividend Taxation in India

12/21/2021

We explain dividend taxation in India, where from FY 2020-21 onwards, the tax incidence of dividends now falls on the shareholder instead of the company issuing the dividends.

ASEAN Briefing

The Completed China-Laos Railway: Bringing Opportunities for ASEAN and the Asia Pacific

12/21/2021

The completed China-Laos railway can transform Laos from a landlocked country into a land-linked hub that connects the wider region.

China Briefing

Belt & Road Weekly Investor Intelligence #60

12/21/2021

This week we examine the attractiveness of Hanoi, Russia’s continuing repositioning towards ASEAN markets, and China's lowering of tariffs.

China Briefing

Fujian Pingtan Extends 15% CIT for Qualified Enterprises Until End of 2025

12/20/2021

Qualified enterprises in Fujian Pingtan Area can enjoy 15% CIT until December 31, 2025 – China’s national CIT rate is 25%.

China Briefing

China Lowers Tariffs on 954 Products from January 1, 2022

12/17/2021

China will lower tariffs on 954 goods and raise tariffs on some other goods in 2022 in a bid to support high-quality development and opening up.

Vietnam Briefing

Q&A: All Eyes on Vietnam: Why 2022 is an Ideal Time to Invest?

12/17/2021

In this Q&A, with Dang Trinh and Thang Vu, we examine reasons why 2022 is an ideal time for investment in Vietnam including market entry options.

ASEAN Briefing

Singapore Provides Funding Package to Spur IPO Growth

12/16/2021

Singapore introduced a new funding package to support high-growth companies raising capital in the country’s public equity market.

China Briefing

How Chinese Financing Is Helping US and German Biotechnology

12/16/2021

We look at two unique case studies in biotechnology collaboration – between China and the United States (BeiGene and Amgen) and China and Germany (Fosun Pharma and BioNTech).